Insight Molecular Financials - Benzinga

Insight Molecular Diagnostics Inc

IMDXNASDAQ

Trade with Public

Trade with Public

$4.00

Last update: Sep 18, 4:00 PM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Insight Molecular Financials

Insight Molecular (IMDX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
CORRECTION: Insight Molecular Q2 Adj. EPS $(0.23) Beats $(0.24) Estimate, Sales $239.000K Miss $437.500K Estimate

Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 23.33 percent increase over losses of $(0.30) per share from

Benzinga Newsdesk

PRO
Insight Molecular Q1 Adj. EPS $(0.28) Misses $(0.26) Estimate, Sales $32.000K Miss $300.000K Estimate

Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 47.37 percent decrease over losses of $(0.19) per share

Benzinga Newsdesk

Earnings Scheduled For May 13, 2026

Benzinga Insights

PRO
Insight Molecular Q4 Adj. EPS $(0.27) Misses $(0.24) Estimate, Sales $1.139M Down From $1.486M Last Year

Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.24) by 13.92 percent. This is a 3.57 percent increase over losses of $(0.28) per share

Benzinga Newsdesk

Earnings Scheduled For March 26, 2026

Benzinga Insights

PRO
Insight Molecular Q3 EPS $(0.34) Misses $(0.21) Estimate, Sales $139.000K Miss $284.000K Estimate

Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.21) by 60.38 percent. This is a 17.07 percent increase over losses of $(0.41) per share

Benzinga Newsdesk